Cargando…

Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV

Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Venturini, Cristina, Houldcroft, Charlotte J., Lazareva, Arina, Wegner, Fanny, Morfopoulou, Sofia, Amrolia, Persis J., Golwala, Zainab, Rao, Anupama, Marks, Stephen D., Simmonds, Jacob, Yoshikawa, Tetsushi, Farrell, Paul J., Cohen, Jeffrey I., Worth, Austen J., Breuer, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589012/
https://www.ncbi.nlm.nih.gov/pubmed/34431085
http://dx.doi.org/10.1111/bjh.17790
_version_ 1784598615065362432
author Venturini, Cristina
Houldcroft, Charlotte J.
Lazareva, Arina
Wegner, Fanny
Morfopoulou, Sofia
Amrolia, Persis J.
Golwala, Zainab
Rao, Anupama
Marks, Stephen D.
Simmonds, Jacob
Yoshikawa, Tetsushi
Farrell, Paul J.
Cohen, Jeffrey I.
Worth, Austen J.
Breuer, Judith
author_facet Venturini, Cristina
Houldcroft, Charlotte J.
Lazareva, Arina
Wegner, Fanny
Morfopoulou, Sofia
Amrolia, Persis J.
Golwala, Zainab
Rao, Anupama
Marks, Stephen D.
Simmonds, Jacob
Yoshikawa, Tetsushi
Farrell, Paul J.
Cohen, Jeffrey I.
Worth, Austen J.
Breuer, Judith
author_sort Venturini, Cristina
collection PubMed
description Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV(+) haematological clones that are lost on successful treatment.
format Online
Article
Text
id pubmed-8589012
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85890122021-11-19 Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV Venturini, Cristina Houldcroft, Charlotte J. Lazareva, Arina Wegner, Fanny Morfopoulou, Sofia Amrolia, Persis J. Golwala, Zainab Rao, Anupama Marks, Stephen D. Simmonds, Jacob Yoshikawa, Tetsushi Farrell, Paul J. Cohen, Jeffrey I. Worth, Austen J. Breuer, Judith Br J Haematol Haematological malignancy–Biology Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV(+) haematological clones that are lost on successful treatment. John Wiley and Sons Inc. 2021-08-24 2021-10 /pmc/articles/PMC8589012/ /pubmed/34431085 http://dx.doi.org/10.1111/bjh.17790 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Haematological malignancy–Biology
Venturini, Cristina
Houldcroft, Charlotte J.
Lazareva, Arina
Wegner, Fanny
Morfopoulou, Sofia
Amrolia, Persis J.
Golwala, Zainab
Rao, Anupama
Marks, Stephen D.
Simmonds, Jacob
Yoshikawa, Tetsushi
Farrell, Paul J.
Cohen, Jeffrey I.
Worth, Austen J.
Breuer, Judith
Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title_full Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title_fullStr Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title_full_unstemmed Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title_short Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
title_sort epstein–barr virus (ebv) deletions as biomarkers of response to treatment of chronic active ebv
topic Haematological malignancy–Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589012/
https://www.ncbi.nlm.nih.gov/pubmed/34431085
http://dx.doi.org/10.1111/bjh.17790
work_keys_str_mv AT venturinicristina epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT houldcroftcharlottej epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT lazarevaarina epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT wegnerfanny epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT morfopoulousofia epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT amroliapersisj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT golwalazainab epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT raoanupama epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT marksstephend epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT simmondsjacob epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT yoshikawatetsushi epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT farrellpaulj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT cohenjeffreyi epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT worthaustenj epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv
AT breuerjudith epsteinbarrvirusebvdeletionsasbiomarkersofresponsetotreatmentofchronicactiveebv